Glaukos Announces Commencement of Phase 2 Corneal Health Clinical Program for Third-Generation iLink Therapy

Glaukos announced that it has commenced a phase 2 clinical program for its third-generation iLink therapy designed to treat keratoconus.

Glaukos’ iLink pharmaceutical platform consists of novel single-use drug formulations that are bio-activated by proprietary systems through the delivery of ultraviolet light to the cornea to induce corneal cross-linking designed to strengthen, stabilize and reshape the cornea. Glaukos’ third-generation iLink therapy is a corneal cross-linking treatment designed to customize the therapeutic capabilities, streamline the patient experience, and build upon Glaukos’ first-generation iLink therapy—iLink Epi-off—and its second-generation iLink investigational therapy—iLink Epi-on.

“As we do with all of our platforms, we continue to drive subsequent generations of future innovation, and we are delighted to announce the commencement of this Phase 2 clinical program for our third-generation iLink therapy,” Thomas Burns, Glaukos president and chief executive officer, said in a company news release. “Our third-generation iLink therapy builds upon our proven iLink platform therapies and we are delighted to have the opportunity to explore what this promising investigational therapy can do for keratoconus patients in our phase 2 trials.”

The third-generation iLink phase 2 clinical program consists of two separate multicenter, randomized, controlled trials designed to evaluate the safety and efficacy of patient-specific, customized versus non-customized treatment patterns for corneal cross-linking and a new investigational laser-based bio-activation system, respectively. The company anticipates it will enroll keratoconus patients across both trials at clinical sites in the United States, Europe, South America and Asia. Both trials are designed to have a primary safety and efficacy follow-up period of 6 months.